Tvardi Therapeutics stock plunges after failed IPF trial data
NegativeFinancial Markets

Tvardi Therapeutics faced a significant setback as its stock plummeted following disappointing results from a trial related to idiopathic pulmonary fibrosis (IPF). This news is crucial as it not only impacts the company's financial standing but also raises concerns about the viability of its treatments, potentially affecting investors and patients alike.
— Curated by the World Pulse Now AI Editorial System